Phase II
During a presentation at the AAT-AD/PD 2020 conference, Axon said AADvac1 showed a disease-modifying effect on Alzheimer’s disease.
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
The companies initiated a Phase II/III trial in Italy, Spain, Germany, France, Japan, Canada and Russia.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 1, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.
“The adjustments we have made to our studies reflect our foremost concern for the safety and well-being of study participants, clinical investigators and their site staffs, our employees and communities as we face this challenging and unpredictable operating environment,” said Warren Huff, Reata’s chief executive officer and president.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.
The World Health Organization is launching a clinical trial in Norway and Spain to assess four of the most promising drugs in the fight against COVID-19, the disease caused by the novel coronavirus that has spread across the globe.
PRESS RELEASES